{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T03:29:21Z","timestamp":1781148561019,"version":"3.54.1"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T00:00:00Z","timestamp":1716681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F31-AG081047"],"award-info":[{"award-number":["F31-AG081047"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["F31-NS131000"],"award-info":[{"award-number":["F31-NS131000"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-NS082168"],"award-info":[{"award-number":["T32-NS082168"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Cognitive changes are heterogeneous in Parkinson\u2019s disease (PD). This study compared whether anticholinergic burden drives differences in cognitive domain performance and empirically-derived PD-cognitive phenotypes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Method<\/jats:title>\n                  <jats:p>A retrospective chart review contained participants (n\u2009=\u2009493) who had idiopathic PD without dementia. Participants\u2019 medications were scored (0\u20133) and summed based on the anticholinergic cognitive burden scale (ACBS). We examined the ACBS\u2019 relationship to five cognitive domain composites (normative z-scores) and three (K-means clustering based) cognitive phenotypes: cognitively intact, low executive function (EF), and predominately impaired EF\/memory. Analyses included Spearman correlations, analysis of covariance, and Pearson chi-squared test.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, phenotypes did not differ in anticholinergic burden, and (after false-discovery-rate corrections) no cognitive domains related. When comparing those above and below the clinically relevant ACBS cutoff (i.e., score\u2009\u22653), no significant phenotype or domain differences were found.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Anticholinergic medication usage did not drive cognitive performance in a large clinical sample of idiopathic PD without dementia.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/arclin\/acae041","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T05:15:23Z","timestamp":1716786923000},"page":"1443-1449","source":"Crossref","is-referenced-by-count":1,"title":["Anticholinergic Medication Burden and Cognitive Subtypes in Parkinson\u2019s Disease without Dementia"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0454-1704","authenticated-orcid":false,"given":"Lauren G","family":"Santos","sequence":"first","affiliation":[{"name":"Department of Clinical and Health Psychology, University of Florida , PO Box 100165 Gainesville, FL 32610-0165"},{"name":"Norman Fixel Institute for Neurological Diseases, University of Florida , 3009 SW Williston Road Gainesville, FL 32608"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E","family":"Kenney","sequence":"additional","affiliation":[{"name":"Department of Clinical and Health Psychology, University of Florida , PO Box 100165 Gainesville, FL 32610-0165"},{"name":"Norman Fixel Institute for Neurological Diseases, University of Florida , 3009 SW Williston Road Gainesville, FL 32608"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Ray","sequence":"additional","affiliation":[{"name":"Department of Clinical and Health Psychology, University of Florida , PO Box 100165 Gainesville, FL 32610-0165"},{"name":"Norman Fixel Institute for Neurological Diseases, University of Florida , 3009 SW Williston Road Gainesville, FL 32608"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Paredes","sequence":"additional","affiliation":[{"name":"Department of Clinical and Health Psychology, University of Florida , PO Box 100165 Gainesville, FL 32610-0165"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianna M","family":"Ratajska","sequence":"additional","affiliation":[{"name":"Department of Clinical and Health Psychology, University of Florida , PO Box 100165 Gainesville, FL 32610-0165"},{"name":"Norman Fixel Institute for Neurological Diseases, University of Florida , 3009 SW Williston Road Gainesville, FL 32608"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Eversole","sequence":"additional","affiliation":[{"name":"Department of Clinical and Health Psychology, University of Florida , PO Box 100165 Gainesville, FL 32610-0165"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavana","family":"Patel","sequence":"additional","affiliation":[{"name":"Norman Fixel Institute for Neurological Diseases, University of Florida , 3009 SW Williston Road Gainesville, FL 32608"},{"name":"Department of Neurology, University of Florida , Box 100236 Gainesville, FL 32610-0236"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E","family":"Rawls","sequence":"additional","affiliation":[{"name":"Norman Fixel Institute for Neurological Diseases, University of Florida , 3009 SW Williston Road Gainesville, FL 32608"},{"name":"Department of Neurology, University of Florida , Box 100236 Gainesville, FL 32610-0236"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S","family":"Okun","sequence":"additional","affiliation":[{"name":"Norman Fixel Institute for Neurological Diseases, University of Florida , 3009 SW Williston Road Gainesville, FL 32608"},{"name":"Department of Neurology, University of Florida , Box 100236 Gainesville, FL 32610-0236"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Bowers","sequence":"additional","affiliation":[{"name":"Department of Clinical and Health Psychology, University of Florida , PO Box 100165 Gainesville, FL 32610-0165"},{"name":"Norman Fixel Institute for Neurological Diseases, University of Florida , 3009 SW Williston Road Gainesville, FL 32608"},{"name":"Department of Neurology, University of Florida , Box 100236 Gainesville, FL 32610-0236"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,26]]},"reference":[{"issue":"8","key":"2024112505555966800_ref1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1002\/mdc3.13347","article-title":"Antimuscarinic anticholinergic medications in Parkinson disease: To prescribe or deprescribe?","volume":"8","author":"Barrett","year":"2021","journal-title":"Movement Disorders Clinical Practice"},{"key":"2024112505555966800_ref2","author":"Bauer","year":"2017","edition":"2nd"},{"issue":"2","key":"2024112505555966800_ref3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1006\/brcg.1999.1083","article-title":"Acute and long-term administration of anticholinergics in Parkinson\u2019s disease: Specific effects on the subcortico-frontal syndrome","volume":"40","author":"B\u00e9dard","year":"1999","journal-title":"Brain and Cognition"},{"issue":"1","key":"2024112505555966800_ref4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2967\/jnumed.111.096578","article-title":"Effectiveness and safety of 18 F-FDG PET in the evaluation of dementia: A review of the recent literature","volume":"53","author":"Bohnen","year":"2012","journal-title":"Journal of Nuclear Medicine"},{"issue":"4","key":"2024112505555966800_ref5","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1474-4422(21)00377-X","article-title":"Cholinergic system changes in Parkinson\u2019s disease: Emerging therapeutic approaches","volume":"21","author":"Bohnen","year":"2022","journal-title":"The Lancet Neurology"},{"issue":"3","key":"2024112505555966800_ref6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","article-title":"Impact of anticholinergics on the aging brain: A review and practical application","volume":"4","author":"Boustani","year":"2008","journal-title":"Aging Health"},{"issue":"2","key":"2024112505555966800_ref7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/phar.2652","article-title":"Anticholinergic medication burden and cognitive function in participants of the ASPREE study","volume":"42","author":"Broder","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"10","key":"2024112505555966800_ref8","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1080\/14740338.2020.1811227","article-title":"Anticholinergic medications and risk of dementia in older adults: Where are we now?","volume":"19","author":"Chatterjee","year":"2020","journal-title":"Expert Opinion on Drug Safety"},{"issue":"8","key":"2024112505555966800_ref9","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: A nested case-control study","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Internal Medicine"},{"issue":"5","key":"2024112505555966800_ref10","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/mds.26595","article-title":"Atropinic (anticholinergic) burden in Parkinson\u2019s disease","volume":"31","author":"De Germay","year":"2016","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"2","key":"2024112505555966800_ref11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ana.410280202","article-title":"Cholinergic deficiency and frontal dysfunction in Parkinson\u2019s disease","volume":"28","author":"Dubois","year":"1990","journal-title":"Annals of Neurology"},{"issue":"2","key":"2024112505555966800_ref12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/jnnp.2009.186239","article-title":"Use of drugs with anticholinergic effect and impact on cognition in Parkinson\u2019s disease: A cohort study","volume":"81","author":"Ehrt","year":"2010","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"4","key":"2024112505555966800_ref13","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/mds.27561","article-title":"Multimodal magnetic resonance imaging investigation of basal forebrain damage and cognitive deficits in Parkinson\u2019s disease","volume":"34","author":"Gargouri","year":"2019","journal-title":"Movement Disorders"},{"key":"2024112505555966800_ref14","volume-title":"Anticholinergic medications","author":"Ghossein","year":"2023"},{"issue":"6","key":"2024112505555966800_ref15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1136\/jnnp.51.6.745","article-title":"The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson\u2019s disease","volume":"51","author":"Gibb","year":"1988","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"1","key":"2024112505555966800_ref16","first-page":"1","article-title":"Cognitive impairment in Parkinson\u2019s disease: A report from a multidisciplinary symposium on unmet needs and future directions to maintain cognitive health","volume":"4","author":"Goldman","year":"2018","journal-title":"NPJ Parkinson\u2019s Disease"},{"issue":"5","key":"2024112505555966800_ref17","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/mds.25857","article-title":"The neurobiological basis of cognitive impairment in Parkinson\u2019s disease","volume":"29","author":"Halliday","year":"2014","journal-title":"Movement Disorders: Official Journal of the Movement Disorder Society"},{"issue":"11","key":"2024112505555966800_ref18","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.parkreldis.2014.09.014","article-title":"The cognition and emotional well-being indices of the Parkinson\u2019s disease questionnaire-39: What do they really measure?","volume":"20","author":"Jones","year":"2014","journal-title":"Parkinsonism & Related Disorders"},{"issue":"4","key":"2024112505555966800_ref19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1017\/S1355617717000017","article-title":"Are Parkinson\u2019s patients more vulnerable to the effects of cardiovascular risk: A neuroimaging and neuropsychological study","volume":"23","author":"Jones","year":"2017","journal-title":"Journal of the International Neuropsychological Society: JINS"},{"issue":"1","key":"2024112505555966800_ref20","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12010054","article-title":"Mapping actuarial criteria for Parkinson\u2019s disease-mild cognitive impairment onto data-driven cognitive phenotypes","volume":"12","author":"Kenney","year":"2022","journal-title":"Brain Sciences"},{"key":"2024112505555966800_ref21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.parkreldis.2021.09.018","article-title":"Normal cognition in Parkinson\u2019s disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [18F]-FEOBV","volume":"91","author":"Legault-Denis","year":"2021","journal-title":"Parkinsonism & Related Disorders"},{"key":"2024112505555966800_ref22","first-page":"1161","volume-title":"Neuropsychological assessment","author":"Lezak","year":"2012","edition":"5th"},{"issue":"6","key":"2024112505555966800_ref23","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1007\/s11606-020-06550-2","article-title":"A cohort study of anticholinergic medication burden and incident dementia and stroke in older adults","volume":"36","author":"Lockery","year":"2021","journal-title":"Journal of General Internal Medicine"},{"issue":"7","key":"2024112505555966800_ref24","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1111\/bcp.14687","article-title":"Cognitive decline associated with anticholinergics, benzodiazepines and Z-drugs: Findings from the Irish Longitudinal Study on Ageing (TILDA)","volume":"87","author":"Moriarty","year":"2021","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"9","key":"2024112505555966800_ref25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11910-013-0377-9","article-title":"Cholinergic dysfunction in Parkinson\u2019s disease","volume":"13","author":"M\u00fcller","year":"2013","journal-title":"Current Neurology and Neuroscience Reports"},{"issue":"6","key":"2024112505555966800_ref26","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/jgs.18279","article-title":"Longitudinal associations of anticholinergic medications on cognition and possible mitigating role of physical activity","volume":"71","author":"Norling","year":"2023","journal-title":"Journal of the American Geriatrics Society"},{"key":"2024112505555966800_ref27","doi-asserted-by":"crossref","first-page":"awae069","DOI":"10.1093\/brain\/awae069","article-title":"Cholinergic changes in Lewy body disease: Implications for presentation, progression and subtypes","volume":"147","author":"Okkels","year":"2024","journal-title":"Brain"},{"key":"2024112505555966800_ref28","volume-title":"Parkinson\u2019s Disease Foundation, New York, NY.","author":"Parkinson\u2019s Disease Foundation","year":"2024"},{"issue":"7","key":"2024112505555966800_ref29","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/mdc3.13319","article-title":"The cholinergic brain in Parkinson\u2019s disease","volume":"8","author":"Pasquini","year":"2021","journal-title":"Movement Disorders Clinical Practice"},{"key":"2024112505555966800_ref30","volume-title":"Neurology","author":"Petrou","year":"2012"},{"issue":"7","key":"2024112505555966800_ref31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/BF00886877","article-title":"Anticholinergic therapy and dementia in patients with Parkinson\u2019s disease","volume":"243","author":"Pondal","year":"1996","journal-title":"Journal of Neurology"},{"issue":"11","key":"2024112505555966800_ref32","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1007\/s00415-020-09977-z","article-title":"Identifying subtypes of mild cognitive impairment in Parkinson\u2019s disease using cluster analysis","volume":"267","author":"Pourzinal","year":"2020","journal-title":"Journal of Neurology"},{"issue":"12","key":"2024112505555966800_ref33","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/brain\/awad226","article-title":"Structural and molecular cholinergic imaging markers of cognitive decline in Parkinson\u2019s disease","volume":"146","author":"Schumacher","year":"2023","journal-title":"Brain"},{"issue":"5","key":"2024112505555966800_ref34","doi-asserted-by":"crossref","first-page":"e64111","DOI":"10.1371\/journal.pone.0064111","article-title":"Cognitive decline in older persons initiating anticholinergic medications","volume":"8","author":"Shah","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"2024112505555966800_ref35","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/phar.2305","article-title":"Association between anticholinergic medication use and risk of dementia among patients with Parkinson\u2019s disease","volume":"39","author":"Sheu","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"5","key":"2024112505555966800_ref36","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1159\/000526863","article-title":"Anticholinergic burden, polypharmacy, and cognition in Parkinson\u2019s disease patients with mild cognitive impairment: A cross-sectional observational study","volume":"51","author":"Sumbul-Sekerci","year":"2023","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"8","key":"2024112505555966800_ref37","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1474-4422(12)70152-7","article-title":"Cognitive impairment in patients with Parkinson\u2019s disease: Diagnosis, biomarkers, and treatment","volume":"11","author":"Svenningsson","year":"2012","journal-title":"The Lancet Neurology"},{"issue":"1\u20132","key":"2024112505555966800_ref38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/00207458108985816","article-title":"Decreased verbal memory associated with anticholinergic treatment in Parkinson\u2019s disease patients","volume":"14","author":"Syndulko","year":"1981","journal-title":"The International Journal of Neuroscience"},{"issue":"4","key":"2024112505555966800_ref39","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/mds.28913","article-title":"Altered cholinergic innervation in de novo Parkinson\u2019s disease with and without cognitive impairment","volume":"37","author":"Van Der Zee","year":"2022","journal-title":"Movement Disorders"},{"issue":"3","key":"2024112505555966800_ref40","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/mds.28360","article-title":"Cholinergic denervation patterns across cognitive domains in Parkinson\u2019s disease","volume":"36","author":"Van Der Zee","year":"2021","journal-title":"Movement Disorders"}],"container-title":["Archives of Clinical Neuropsychology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/acn\/article-pdf\/39\/8\/1443\/60784273\/acae041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/acn\/article-pdf\/39\/8\/1443\/60784273\/acae041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T05:56:31Z","timestamp":1732514191000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/acn\/article\/39\/8\/1443\/7682423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,26]]},"references-count":40,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,5,26]]},"published-print":{"date-parts":[[2024,11,22]]}},"URL":"https:\/\/doi.org\/10.1093\/arclin\/acae041","relation":{},"ISSN":["1873-5843"],"issn-type":[{"value":"1873-5843","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,5,26]]}}}